Dianthus Therapeutics (NASDAQ:DNTH) just reported results for the first quarter of 2024.
- Dianthus Therapeutics reported earnings per share of -54 cents. This was below the analyst estimate for EPS of -44 cents.
- The company reported revenue of $874,000.
- This was 90% better than the analyst estimate for revenue of $460,000.